-
ESMO 2023 | SKB264 (TROP2-ADC) Shows Promise in the Treatment of HR+/HER2- Metastatic Breast Cancer, Advancing in Multiple Cancer Types
TROP2 (Trophoblast Cell-Surface Antigen 2) is highly expressed in various solid tumors, making it a hot target in the field of oncology. The development of antibody-drug conjugates (ADCs) targeting this antigen has garnered significant attention. At the 2023 European Society for Medical Oncology (ESMO) Congress held in Madrid, Spain from October 20th to 24th, an…
-
ESMO Big Shot Interview | pCR reaches 39.8%, short-course radiotherapy followed by cetuximab in combination with CAPOX brings significant benefits to locally advanced rectal cancer patients
The 2023 European Society for Medical Oncology (ESMO) Annual Meeting was held in Madrid, Spain, from October 20th to 24th. Professor Tao Zhang and Professor Kaixiong Tao from Tongji Medical College of Huazhong University of Science and Technology and their team conducted a randomized Phase III trial, the UNION study (Abstract Number: LBA25), entitled “Neoadjuvant…
-
ESMO China Voice | Professor Sheng Xinan Reports RENOTORCH Study, Sharing the First “Domestic Innovation” Immune Combination Therapy for First-Line
The combination of immune checkpoint inhibitors and anti-angiogenic therapy has become a first-line treatment option for advanced renal cell carcinoma (aRCC), with previous studies including patients of all IMDC risk levels. During a dedicated session on urological oncology at the 2023 ESMO Congress, Professor Sheng Xinan from Peking University Cancer Hospital, on behalf of a…
-
ESMO China Voice | Professor Xiaojia Wang: Aromatase Inhibitor Treatment for mBC Progression? Anlotinib Combined with Fulvestrant Offers New Hope
Hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer accounts for over 70% of all breast cancers[1]. The use of CDK4/6 inhibitors has brought about a breakthrough in the survival of these late-stage patients. However, some recurrent metastatic patients may develop endocrine resistance, reducing the efficacy of treatment. The European Society…
-
IDWeek Commentary | Dr. Yonghong Xiao: Intestinal colonization with MDRO, horizontal transmission and risk for bloodstream infection
Editor’s Note: Bacterial drug resistance is a significant challenge in the global public health field. Multidrug-resistant organisms (MDROs), represented by carbapenem-resistant Enterobacteriaceae (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Pseudomonas aeruginosa…
-
IDWeek Live interview: Clinical Trials in Fungal Diseases That May Change Your Practice
Editor’s Note: In a special session titled “Clinical Trials That May Change Your Practice” at the 2023 Infectious Diseases Week (IDWeek 2023), Dr. George R. Thompson III of University of…
-
IDWeek Live Interview | Dr. Murat Akova: When to Discontinue Antibiotics in Febrile Neutropenia?
Editor’s Note: The normal immune function of the body is crucial in defending against invading pathogens and maintaining the stability of the internal environment. In recent years, our understanding of…
-
IDWeek Live Interview | Dr. Patty Wright Summarizes Hot Topics in the Field of Infectious Diseases
Editor’s Note: The IDWeek 2023 took place in Boston from October 11 to 15. On the first day during the “What’s Hot in ID + HIV” session, Dr. Patty W.…
Connecting Medical Expertise through Media